Hypertrophic cardiomyopathy — a thickening of the heart muscle — can obstruct the flow of blood to the body and is associated with disturbances in the heart’s electrical signals. It is the leading cause of sudden cardiac death in young athletes and is among the more common inherited cardiovascular diseases, affecting approximately one person in 500. While some patients are asymptomatic, others may experience chest pain, shortness of breath, fatigue, palpitations, light-headedness, dizziness and blackouts. Complications can include arrhythmias (atrial fibrillation and ventricular tachycardia), endocarditis (infection of the heart) and sudden cardiac death. Although symptoms or an abnormal electrocardiogram may indicate hypertrophic cardiomyopathy, a definitive diagnosis is made via echocardiogram or other imaging study techniques. Because of its genetic component, first-degree relatives of those who have the condition should also be screened.
The UCLA Division of Cardiology and Ahmanson-UCLA Cardiomyopathy Center offer a comprehensive hypertrophic cardiomyopathy program with a team of experts dedicated to the diagnosis and treatment of this complex condition. Cardiologists who focus on the disorder collaborate closely with cardiac imaging specialists, interventional cardiologists, electrophysiologists and surgeons to offer a full range of treatments. UCLA genetics experts provide pedigree analysis and genetic counseling to expand the scope of care to include family members who may share this inherited condition. The UCLA Division of Cardiology and Ahmanson-UCLA Cardiomyopathy Center offer patients with the full range of heart disorders comprehensive care that is rated among the nation’s best in the latest rankings by U.S. News & World Report.
All patients referred in our hypertrophic cardiomyopathy will undergo comprehensive evaluation tailored to each individual patient. Each visit will conclude with patient education so that you can be informed about your disease process and treatment plan.
Management of hypertrophic cardiomyopathy can be complex and requires highly specialized expertise to determine the most appropriate therapies. Patients must be carefully assessed to determine their risk of disability or death.
UCLA offers the latest medical therapies. For patients whose symptoms persist despite medications and for patients with appropriate indications, surgical interventions, minimally invasive procedures and electrophysiologic treatments may be appropriate. Treatments include:
UCLA Westwood Campus
Arnold S. Baas, MD - Medical Director, Hypertrophic Cardiomyopathy Program, Advanced Heart Failure
Richard J. Shemin, MD - Surgical Director, Hypertrophic Cardiomyopathy Program, Cardiac Surgery
Ali Nsair, MD - Co-Director, Hypertrophic Cardiomyopathy Program
Olcay Aksoy, MD - Interventional Cardiology
Jamil A. Aboulhosn, MD - Adult Congenital Cardiac Disease
Jason Bradfield, MD - Electrophysiology
Ashley Fan, PharmD - Advanced Heart Failure Pharmacy